| Term 
 
        | Calcium carbonate brand names |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | calcium carbonate indications |  | Definition 
 
        | most common oral prep for mild hypocalcemia, osteomalacia, rickets osteoporosis, renal osteodystrophy |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | not absorbed well without HCl, take with food |  | 
        |  | 
        
        | Term 
 
        | calcium carbonate side effects |  | Definition 
 
        | more GI effects than other preps, mild alkali syndrome leading to hypercalcemia, decreased PTH, hyperphosphatemia, kidney stones, renal failure |  | 
        |  | 
        
        | Term 
 
        | calcium citrate brand name |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | more soluble, better BA, can be taken without food |  | 
        |  | 
        
        | Term 
 
        | dibasic calcium phosphate |  | Definition 
 
        | supplies both calcium and phosphate (oral) |  | 
        |  | 
        
        | Term 
 
        | oral calcium salt side effects |  | Definition 
 
        | GI: constipation, intestinal bloating, gas (esp calcium carb) |  | 
        |  | 
        
        | Term 
 
        | oral calcium salt interactions |  | Definition 
 
        | decreased absorption of fluoride, iron, zinc, beta blockers, salicylates, phenytoin, bisphosphanates, tetracyclines, ciprofloxacin |  | 
        |  | 
        
        | Term 
 
        | oral calcium salt new concerns |  | Definition 
 
        | possible increased heart attack risk (no definitive evidence) |  | 
        |  | 
        
        | Term 
 
        | calcium gluconate route of admin and % Ca |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | calcium gluconate indication |  | Definition 
 
        | drug of choice for IV therapy in acute hypocalcemic tetany (least irritating to veins, infuse slowly to avoid arrhythmias) |  | 
        |  | 
        
        | Term 
 
        | calcium gluceptate route of admin, % Ca, unique characteristic |  | Definition 
 
        | IV or IM, 22% Ca, only one that is not irritating on IM injection |  | 
        |  | 
        
        | Term 
 
        | cholecalciferol, route of admin, brand, and what is it? |  | Definition 
 
        | oral tablets, Delta-D, pure D3 |  | 
        |  | 
        
        | Term 
 
        | ergocalciferol, route of admin, brands, what it is |  | Definition 
 
        | oral or IM, calciferol, drisdol, pure D2 |  | 
        |  | 
        
        | Term 
 
        | dihydrotachysterol, brands, what it is, route of admin |  | Definition 
 
        | DHT, Hytakerol, Roxane; reduced form of D2, oral |  | 
        |  | 
        
        | Term 
 
        | dihydrotachysterol indication, for what population |  | Definition 
 
        | hyperparathyroidism secondary to renal failure, safer drug with renal failure (does not require renal 1-hydroxylation) |  | 
        |  | 
        
        | Term 
 
        | doxercalciferol; brand, what it is |  | Definition 
 
        | Hectoral, newer synthetic oral analog, doesn't require 1-hydroxylation (similar to dihydrotachysterol) |  | 
        |  | 
        
        | Term 
 
        | calcifediol; brand, what population is it used in, route of admin |  | Definition 
 
        | Calderol, does not require liver 25-hydroxylation, safer in liver disease, oral capsules |  | 
        |  | 
        
        | Term 
 
        | Calcitriol, what it is, route of admin |  | Definition 
 
        | 1,25 OH2-D3, the final active hormone, no activation required, clinically most important, oral or injection |  | 
        |  | 
        
        | Term 
 
        | paricalcitol and maxicalcitol; used for, route of admin |  | Definition 
 
        | suppress excess PTH production without causing hypercalcemia; used in treating hyperparathyroidism but not for enhancing Ca abosrption, adminstered IV |  | 
        |  | 
        
        | Term 
 
        | calcipotriene and calcitriol ointment; used for |  | Definition 
 
        | skin ointment preps approved for treatment of psoriasis (vitamin D3 analog) |  | 
        |  | 
        
        | Term 
 
        | cinacalcet; brand, what it is, indication, advantage |  | Definition 
 
        | Sensipar, new group of "calcium sensor mimetics", decreases amount of Ca needed to supress PTH release, used for hyperparathyroidism, normalizes serum calcium without altering bone density |  | 
        |  | 
        
        | Term 
 
        | Calcitonin; what it is, MOA |  | Definition 
 
        | 32 aa polypeptide secreted from thyroid when hypercalcemic, decreases calcium release from bone (inhibits osteoclasts), stimulates calcium and phosphate excretion by kidneys, acts as agonist on calcitonin receptors (GPCRs that increase cAMP) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | acute hypercalcemia, hyperphosphatemia, Paget's, osteoporosis |  | 
        |  | 
        
        | Term 
 
        | bisphosphanates; structure and mechanism |  | Definition 
 
        | analogs of pyrophosphate, bind bone matrix, inhibit osteoclasts, decrease bone turnover |  | 
        |  | 
        
        | Term 
 
        | bisphosphanates; uses, advantages/disadvantages |  | Definition 
 
        | Paget's, hypercalcemia, osteoporosis; oral, non-antigenic, cheaper, may decrease bone formation |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | poorly abosrbed, esp with food, should be taken on empty stomach, excreted by kidney (avoid renal), persist in bone for months/years |  | 
        |  | 
        
        | Term 
 
        | bisphosphanate side effects |  | Definition 
 
        | abdominal pain, nausea, diarrhea, vomiting, osteonecrosis of jaw (ONJ), femur fractures, esophageal cancer |  | 
        |  | 
        
        | Term 
 
        | oral bisphophonate directions |  | Definition 
 
        | overnight fast, take while upright, lots of water, no food for 30 min, remain upright 30 minutes |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | alendronate (generic), risedronate (delayed release prep), tiludronate, ibandronate (oral or IV) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | IV use for prevention and treatement, once per year or every other year injection, risk for renal impairment |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | oral (daily or monthly) or IV (every 3 months) |  | 
        |  | 
        
        | Term 
 
        | teriparatide; brand, what is it, indications |  | Definition 
 
        | Forteo, synthetic human PTH [1-34], hypoparathyroidism, osteoporosis with high fracture risk or glucocorticoid-induced |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | first drug that clearly increases bone formation, daily injection stimulates bone (chronic presence decreases bone), daily SC injection, short action |  | 
        |  | 
        
        | Term 
 
        | teriparatide side effects |  | Definition 
 
        | nausea, cramps, headache, bone cancer concern |  | 
        |  | 
        
        | Term 
 
        | denosumab; properties and mechanism |  | Definition 
 
        | monoclonal antibody (peptide injection) against RANK-L (a cytokine that activates osteoclasts, promotes resorption), denosumab bind RANK-L and prevents RANK activtion (decreasing bone degradation) |  | 
        |  | 
        
        | Term 
 
        | denosumab indication/dose |  | Definition 
 
        | injection given twice per year for postmenopausal women with osteoporosis with history or high risk of fracture or failed other therapy, also to treat bone metastases |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | long-term suppression: ONJ, fracture, delayed fracture healing side effects: back, muscle, bone pain, elevated cholesterol, urinary bladder infections
 |  | 
        |  | 
        
        | Term 
 
        | denosumab contraindication |  | Definition 
 
        | patients with hypocalcemia |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | inhibits bone resorption, quite toxic, 3rd choice after calcitonin, bisphosphonates for hypercalcemia, Paget's, osteoporosis |  | 
        |  | 
        
        | Term 
 
        | Plicamycin (aka mithramycin) |  | Definition 
 
        | cytotoxic antibiotic that decreases plasma Ca by osteoclast toxicity, bone marrow suppression makes it useful in cancer, last resort for hypercalcemia, Paget's, osteoporosis; Useful for hypercalcemia of malignancy |  | 
        |  | 
        
        | Term 
 
        | prednisone and other glucocorticoids |  | Definition 
 
        | decrease hypercalcemia by inhibiting gut Ca absorption and toxic to immune cells, danger of osteoporosis with long-term use |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | stimulates osteoblasts, increases bone formation, increases bone fragility at higher doses |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | narrow therapeutic window, highly toxic due to inhibition of respiratory and glycolytic enzymes |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | IV Ca salts for acute tetany Oral Ca salts for longer-term therapy
 Vitamin D preparation plus adequate dietary Ca
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | treat cause - hyperparathyroidism, adrenocorticall deficiency Acute hypercalcemia: furosemide plus IV saline for diuresis and calciuresis
 Vitamin D toxicity, sarcoidosis: glucocorticoids
 hypercalcemia of malignancy: glucocorticoids, calcitonin, bisphosphonates, gallium nitrate, plicamycin
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | replacement sex steroids plus Ca bisphosphonates
 calcitonin
 teriparatide
 |  | 
        |  | 
        
        | Term 
 
        | therapy of Paget's disease |  | Definition 
 
        | bisphosphonates, calcitonin, plicamycin |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | rapid first pass metabolism in liver when given orally |  | 
        |  | 
        
        | Term 
 
        | slow-release depot forms of estradiol |  | Definition 
 
        | estradiol valerate, estradiol cypionate |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | mainly used in HRT and hypogonadism |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | most common of several natural estrogen preps, contains estrone and estriol isolated from pregnant mare urine (Premarin) |  | 
        |  | 
        
        | Term 
 
        | conjugated estrogen indications |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | ethinyl estradiol and mestranol (prodrug) |  | Definition 
 
        | synthetic estradiol analog, ethinyl group slows metabolism, increases potency, oral effectiveness, commonly used in oral contraceptives and some use in HRT |  | 
        |  | 
        
        | Term 
 
        | diethylstilbestrol (DES, Stilphostrol) |  | Definition 
 
        | non-steroidal estrogen, oral, very potent, toxic, use in cancer |  | 
        |  | 
        
        | Term 
 
        | low dose estrogens used for |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | higher dose estrogens used for |  | Definition 
 
        | epiphysial closure, sexual development, gonadotropins for fertility |  | 
        |  | 
        
        | Term 
 
        | oral contraceptives, HRT, oophorectomy treatment |  | Definition 
 
        | estrogen in combination with progestin |  | 
        |  | 
        
        | Term 
 
        | estrogens; minor side effects |  | Definition 
 
        | nausea, edema most common, breast tenderness, hyperpigmentation |  | 
        |  | 
        
        | Term 
 
        | estrogens; more significant side effects |  | Definition 
 
        | migraine, cholestasis, insulin resistance, liver/gall bladder disease, thrombophlebitis, endometrial hyperplasia (cancer, decreased by including progestins), gynecomastia, teratogenesis, metabolic changes |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | IM, creams, suppositories, slow release IUD, micronized oral prep, safer than synthetic progestins for long term HRT use |  | 
        |  | 
        
        | Term 
 
        | medoxyprogesterone acetate, hydroxyprogesterone caproate, megestrol acetate |  | Definition 
 
        | synthetic progestin, structurally related to progesterone (21 carbons), exert mainly progesterone-like effects, for HRT, cancer, contraception |  | 
        |  | 
        
        | Term 
 
        | norethindrone acetate, norgestrel, ethynodiol |  | Definition 
 
        | synthetic progestin, structurally related to testosterone (18 carbons), aka impeded androgens, usually used in oral contraceptive |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | synthetic progestin, anti-androgenic and anti-mineralocorticoid, used in most popular new oral contraceptives |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | combo with estrogens for contraception/HRT, uterine bleeding due to endometrial hyperplasia, edometriosis, metastatic endometrial and breast cancer, diagnostic for estrogen secretion and endometrial responsiveness |  | 
        |  | 
        
        | Term 
 
        | Progestin adverse effects |  | Definition 
 
        | androgenic progestins: acne, weight gain, masculinization, altered libido, decreased HDL, increased LDL All progestins: menstrual changes, nausea, bloating, teratogenesis
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | SERM, orally effective, used for agonist effect on bone (osteoporosis), no risk of cancer/uterine cancer because antagonist at these receptors, causes menopause symptoms and clotting |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | SERM, orally effective, long used as anti-estrogen, found to be agonist on some receptors, antagonist on breast (used for breast cancer prevention), uterine cancer risk, thrombosis risk, causes menopause symptoms, decrease osteoporosis and heart disease risk |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | first and only pure estrogen antagonist for breast cancer |  | 
        |  | 
        
        | Term 
 
        | shared properties of combination oral contraceptive pills |  | Definition 
 
        | most widely used contraceptives, all contain ethinyl estradiol or mestranol (few) plus a "19-nor" progestin (norethindrone, norgestrel/levonorgestrel, norgestimate, drosperinone), most are fixed combos (some employ sequential changes) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | not androgenic or estrogenic used in combo with ethinyl estradiol |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 84 days of active pills, 7 days of inactive pill (1 period every 3 months) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | similar to Seasonale but contains low ethinyl estradiol in final 7 pills |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | similar to Yasmin (has drosperinone as progestin) but has lower ethinyl estradiol and 24 active pills per 28 day cycle |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 24 instead of 21 active pills per 28 day cycle, ethinyl estradiol dose now only 10ug (lowest ever) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | first continuous combo contraceptive, low dose ethinyl estradiol plus levonorgestrel, eliminates menstruation after some breakthrough spotting, similar to progestin-only pills |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | first combo contraceptive transdermal patch worn for 3 weeks, off for 1 week |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | new 3 week combo controceptive vaginal ring, ethinyl estradiol plus etonogestrel (a new progestin) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | new chewable combo contraceptive |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | new four-phase pill oral estrogen (estradiol valerate) and new progestin (dienogest), estrogen alone on days 1-2 and 25-26 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | inhibits ovulation by disrupting cyclical release of gonadotropins (example of feedback suppressive therapy) |  | 
        |  | 
        
        | Term 
 
        | Combination Contraceptive pill adverse effects - minor |  | Definition 
 
        | estrogen effects: nausea, irritability, headache, fluid retention, cyclic weight gain, breast enlargement/tenderness, menstrual changes, altered libido Progestin effects: Nausea, bloating, menstrual changes, depression, fatigue
 |  | 
        |  | 
        
        | Term 
 
        | Combo contraceptives serious adverse effects |  | Definition 
 
        | hypertension, lipid changes, clotting, stroke, MI, endometriosis (combos decrease), ovarian cancer, breast cancer, glucose intolerance, liver/gall bladder disease, teratogenesis |  | 
        |  | 
        
        | Term 
 
        | Combo contraceptives contraindications |  | Definition 
 
        | Absolute: pregnancy, estrogen-responsive tumor Relative:  thromboembolic disease, HTN, diabetes, liver disease, smoking in older women
 |  | 
        |  | 
        
        | Term 
 
        | OCs decrease response to these drugs |  | Definition 
 
        | acetaminophen, warfarin, thyroxine, antidiabetic drugs |  | 
        |  | 
        
        | Term 
 
        | OCs increase response to these drugs |  | Definition 
 
        | cyclosporine, imipramine, theophylline, corticosteroids, BNZ |  | 
        |  | 
        
        | Term 
 
        | OC efficacy reduced by these drugs |  | Definition 
 
        | ampicillin, tetracycline, neomycin, rifampin, barbs, phenytoin, carbamazepine |  | 
        |  | 
        
        | Term 
 
        | OCs efficacy increased by these drugs |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | norethindrone (Micronor) or norgesterel (Ovrette) |  | Definition 
 
        | progestin only "mini-pills", avoid estrogen adverse effects, but less effective (99.5%), taken daily, lack of regular bleeding, ovulation still occurs, used when estrogens contraindicated (breast feeding, breast cancer, migraine, HTN, older smokers, liver/gall bladder disease, thrombotic disease) |  | 
        |  | 
        
        | Term 
 
        | medroxyprogesterone acetate (Depo-Provera) |  | Definition 
 
        | IM injections every 3 months, concern due to possible toxicity, delayed recovery of fertility (not good for those that still desire pregnancy later) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | single-rod implant inside upper arm, effective for 3 years, risk of irregular bleeding |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | emergency contraceptive containing levonorgestrel only, 2 pills within 72 hrs |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | emergency contraceptive, contains levonorgestrel only, 2 pills 12 hr apart within 72 hrs |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | emergency contraceptive, contains ulipristal (progesterone mixed agonist/antagonist related to mifepristone, an anti-progestin), can be taken up to 5 days after intercourse |  | 
        |  | 
        
        | Term 
 
        | RU 486 - Mifepristone (Mifeprex) |  | Definition 
 
        | abortefactient, progesterone receptor antagonist, disrupts maintenance of endometrium, also increases prostaglandin levels stimulating uterine contraction (induce safe abortion) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 3 x 200 mg tablets in single dose on first day, if no abortion take 2 x 200 ug misoprostol tablets in single dose, on day 14 return visit to confirm termination (95% effective) |  | 
        |  | 
        
        | Term 
 
        | Mifepristone/misoprostol adverse effects |  | Definition 
 
        | vaginal bleeding, severe abdominal pain, transient nausea, vomiting, diarrhea, headache |  | 
        |  | 
        
        | Term 
 
        | methotrexate plus misoprostol |  | Definition 
 
        | not approved for abortion but effective and used, folic acid antagonist and cytotoxic to trophoblast |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | induce ovulation, dopamine agonist, orally effective, inhibits prolactin secretion by activating pituitary DA receptors |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | induce ovulation, weak androgen, orally effective, anti-estrogen to inhibit gonadotropin secretion, some progestin activity, used when ovulation prob due to endometriosis |  | 
        |  | 
        
        | Term 
 
        | clomiphene (Clomid, Serophene) |  | Definition 
 
        | induce ovulation, non-steroidal anti-estrogen, orally effective, reduces estrogen feedback inhibition of gonadotropin release, stimulates ovaries, also partial estrogen agonist, induces ovulation in 80%, 10% multiple births, causes ovary enlargement, menopause symptoms, used for oligospermia in males |  | 
        |  | 
        
        | Term 
 
        | Human chorionic gonadotropin (hCG) (Profasi, APL) |  | Definition 
 
        | peptide (IM), induce ovulation when pituitary defect, similar activity to LH, longer duration, from urine of preg women, also treat male infertility, hypogonadism in both sexes |  | 
        |  | 
        
        | Term 
 
        | Menotropins (human menopausal gonadotropins, hMG, Pergonal) |  | Definition 
 
        | peptide, induce ovulation when pituitary defect, LH and FSH activity, urine of postmeno women, used with hCG |  | 
        |  | 
        
        | Term 
 
        | Ovulation induction regimen |  | Definition 
 
        | low doses of menotropins plus hCG for 9-12 days for follicular development, then large dose of hCG alone for LH surge, induce ovulation (multiple births common), used in vitro fertilization, spermatogenesis |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | peptides, IM or SC (Urofollitropin, recombinant follitropin alpha subunit or beta subunit) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | synthetic GnRH, pulsatile admin (mimic physio release pattern), when hypothalamus is defective |  | 
        |  | 
        
        | Term 
 
        | oxytocin (Pitocin, Syntocinon) |  | Definition 
 
        | augmentation of labor or induction (high dose), small peptide hormone from posterior pituitary, agonist at GPCR, stimulates uterine SM contraction, stimulates PG production |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | fetal HR closely monitored, too much uterine contraction can reduce fetal circulation, may need B2-adrenergic agonist |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | uterine contraction, small AA metabolites, act on GPCR to increase calcium, muscle contraction, induce cervical ripening at low doses |  | 
        |  | 
        
        | Term 
 
        | dinoprostone, carboprost, misoprostol |  | Definition 
 
        | prostaglandins, misoprostol has less GI effects and fever |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | second trimester abortions, often used together with other agents, local application of dinoprostone for cervical ripening |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | mediate painful contractions during dysmenorrhea (indomethacin, PG synthesis inhibitor effective therapy) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | plant compounds, increase frequency/force of uterine contractions, contraindicated in HTN Preps include: ergonovine, methylergonovine
 Used for: post-partum or after abortion to control bleeding, maintain contraction
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | inhibit uterine motility, delay/prevent premature delivery, examples include: terbutaline, magnesium salts, nifedipine, nicardipine, indomethacin |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | most commonly used B2-adrenergic agonist for premature labor, IV to stop labor, then oral for maintenance, reflex tachycardia, increase cardiac output, hyperglycemia |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | eclamptic seizures (Mg sulfate), IV to inhibit uterine motility, Mg gluconate oral for maintenance, high concentrations can cause respiratory depression and cardiac arrest |  | 
        |  | 
        
        | Term 
 
        | Nifedipine and nicardipine |  | Definition 
 
        | effective tocolytic agents, calcium channel blockers, without reducing placental blood flow |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | tocolytic, PG synthetase inhibitor, fetal/neonatal toxicities limit use |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | rapid metabolism, limited parenteral effectiveness, not orally effective, topical preps effective |  | 
        |  | 
        
        | Term 
 
        | Andro LA, Depo-testosterone |  | Definition 
 
        | testosterone esters, IM injection lasting 2-4 wks |  | 
        |  | 
        
        | Term 
 
        | methyltestosterone (Android) |  | Definition 
 
        | modified 17 alkyl to decrease metabolism, orally effective, androgenic steroid, hepatotoxic, short half life |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | replacement therapy, anabolic effects, breast cancer, erythropoiesis in some types of anemia |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 17 alkyl testosterone analog, used in hereditary angioneuretic edema (liver effect) |  | 
        |  | 
        
        | Term 
 
        | testosterone adverse effects |  | Definition 
 
        | adverse effects: masculinization, feminization in men, testicular atrophy, prostate enlargement, acne, liver disease (17 alkyl synthetics), lipid changes, salt/water retention, HTN |  | 
        |  | 
        
        | Term 
 
        | Oxandrolone, oxymetholone, stanozolol |  | Definition 
 
        | higher ratio of anabolic to androgenic effectiveness, less masculinizing side effects, used by athletes, SARMS?, all are schedule III |  | 
        |  | 
        
        | Term 
 
        | testosterone-like dietary supplements |  | Definition 
 
        | androstenedione, dehydroepiandrosterone (DHEA) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | anti-androgen, GnRH analog, modified synthetic peptide, long DOA, reduces gonadotropin release (initially increase by desensitization) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | used together to treat prostate cancer and hirsutism, anti-estrogen effects in breast cancer |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | new GnRH antagonist analog, anti-androgen for advanced prostate cancer, peptide |  | 
        |  | 
        
        | Term 
 
        | medroxyprogesterone acetate |  | Definition 
 
        | inhibit GnRH release, induce chemical castration for sex offenders |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | orally effective non-steroidal androgen receptor antagonist, for prostate cancer, useful early in course of GnRH agonist therapy |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | orally effective antagonist at mineralocorticoid and androgen receptors, also inhibits androgen synthesis, used alone or with oral contraceptives to treat hirsutism |  | 
        |  | 
        
        | Term 
 
        | finasteride (propecia, proscar) |  | Definition 
 
        | orally effective 5a-reductase inhibitor, block conversion of testosterone to DHT, used for BPH, baldness |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | class of viruses ssRNA that create dsDNA, HIV is example |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | class of viruses ssRNA that create dsDNA copies, most efficient vector for gene delivery |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | class of viruses with dsDNA, cause respiratory, intestinal and eye infections |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | class of small, ssDNA, insert DNA on chromosome 19 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | class of dsDNA viruses, impact neurons |  | 
        |  | 
        
        | Term 
 
        | Leber's congenital amaurosis (LCA) |  | Definition 
 
        | defect in RPE65, AAV used |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | insert size 4.7 kb, high immune response |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | integration occurs with this vector |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | plasma/lipid complex contains DNA sequences encoding HLA-B7 and beta2 microglobulin, form a MCH Class I |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | used by injecting directly into tumor lesion to direct an immune response against metastatic tumors |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | antisense phosphorothioate oligonucleotide, blocks replication of mRNA, 21 nucleotides long |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | complimentary to mRNA transcribed from major immediate-early transcriptional unit of CMV, inhibits replication, used for local treatment of CMV retinitis with AIDS |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | protein product of MDR1, functions as an efflux transporter for lipophilic xenobiotics |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | MDR1 T/T mutation causes decreased concentrations of these chemotherapies |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | anesthesia, patients with plasma cholinesterase deficiency remain paralyzed for longer, dibucaine number used |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | slow acetylator gets peripheral neuropathy, rapid acetylator has potential therapy failure |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | slow acetylator develops SLE, fast acetylator need higher doses |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | slow acetylator has more bladder cancer, slow acetylator has less bladder cancer |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | largest phenotypical variability among CYP family, more than 70 variant alleles |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | increased CYP2D6 activity |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | decreased CYP2D6 activity |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | extensive 2D6 activity means more morphine, PM means less analgesia |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | EM 2D6 means mild side effects, PM means neurological problems |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | EM 2D6 causes no change, PM causes no change |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 2C9 most deficient activity alleles among ethnic groups, warfarin, tolbutamide and phenytoin |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | taken up by nerve cells by same mechanisms as noradrenaline, message is not passed on, muscles relax, blood vessels widen, decreases BP |  | 
        |  | 
        
        | Term 
 
        | debrisoquine-4-hydroxylase |  | Definition 
 
        | 5-10% of caucasians are PM, caused by several mutant 2D6 alleles |  | 
        |  | 
        
        | Term 
 
        | tamoxifen metabolic pathway |  | Definition 
 
        | metabolized by 2D6 and multiple other enzymes |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | assumed to be more sensitive to mediaction, phase II metabolism appears to depressed |  | 
        |  | 
        
        | Term 
 
        | liver metabolism in elderly |  | Definition 
 
        | decreased phase I activity, CYP3A4 unchanged, 2D6/2C9/2C19/1A2 activities reduced |  | 
        |  | 
        
        | Term 
 
        | barbs, diazepam, propranolol, verapamil |  | Definition 
 
        | high extraction ratio drugs, hepatic clearance, reduce doses |  | 
        |  | 
        
        | Term 
 
        | ethanol, prazosin, warfarin |  | Definition 
 
        | low extraction ratio drugs, no change in dose |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 1A2 inhibition, increased olanzepine, causes rigidity and falls, PK |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | synergistic hypoglycemia, causes falls and fatigue, PD |  | 
        |  | 
        
        | Term 
 
        | tolterodine and donepezil |  | Definition 
 
        | antagonism, causes decreased cognition, PD |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 3A4 induction, decreased warfarin, increased risk of strokes, PD |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | decreased platelet function, bleeding, herbal-drug interaction |  | 
        |  | 
        
        | Term 
 
        | benzodiazepines and alcohol |  | Definition 
 
        | synergistic CNS depression, falls |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | preferred antihypertensive, hypokalemia, hyperglycemia, hyperuricemia are more relevant due to arrhythmias, DM, and gout |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | drug of choice for anti-inflammatory |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | analgesic and atipyretic of choice during pregnancy |  | 
        |  | 
        
        | Term 
 
        | cold medications with sympathomimetics |  | Definition 
 
        | may lead to vascular-mediated congenital defects in the fetus |  | 
        |  | 
        
        | Term 
 
        | penicillins and cephalosporins |  | Definition 
 
        | safest for treatment of bacterial infections during pregnancy |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | gray baby syndrome, phase II glucuronidation deficient |  | 
        |  | 
        
        | Term 
 
        | carbamazepine and valproic acid |  | Definition 
 
        | dietary suppl with folic acid recommended to prevent neural tube defects |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | preferred antihypertensives in pregnancy |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | for acne vulgaris, highly teratogenic! |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | for psoriasis, highly teratogenic! |  | 
        |  | 
        
        | Term 
 
        | phenothiazines, metoclopramide and ondansetron |  | Definition 
 
        | used for N/V during pregnancy |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | used for diarrhea during pregnancy, poorly absorbed |  | 
        |  |